Nice try except the following speak volumes and in truth I have been consistently buying shares all along the way for the past two years. You ask what is going to differentiate this year from any other year post 2009. Glad I can be of some assistance to the New Investors!!! Need links??? Just let me know!!! I got em and then some!!!
And most importantly, and this is really going to differentiate this year from last year, is to focus on the development of the abuse resistant products, which is really the reason this Company, to an extent, was founded, is to do those products. And we are closer now than we ever have been. We think within this fiscal year those will be scaled up and ready to enter biostudies. If you're familiar with the valuation accretion curve in pharmaceuticals, a little effort goes a long way in terms of creating value in pharmaceutical products. What I mean by that is that if you have a formula that's worth X, if you can make a pilot batch, it's X times two. If you can make a commercial batch, well, it's X times some number, and finally, if you can do a bio study that's successful, well, it's X times many, many times. And that's our goal here. Okay?
So for not an extraordinary amount invested, you get a lot in return.
So in summary, our financials continue to contain metrics that (inaudible), revenues are increasing, losses are decreasing, we are moving towards breakeven and expect that trend to continue. The new product lines are growing nicely and we also have three recently approved products that are scheduled for launch.
So comparing revenues from a quarter one year ago, manufacturing revenues have increased over 200% and royalty revenues have increased more than 700%. Clearly, Elite is growing substantially as we continue to add products. Elite is preparing to launch three new products for its portfolio, two strengths of the Phentermine capsules and an Naltrexone tablet product.
Market Data 
Markets 
AI
